Takeda Grants License To Neurocrine Biosciences For Seven Pipeline Programs

Neurocrine Biosciences, Inc. (NBIX) and Takeda Pharmaceutical Company Limited (TAK) have entered a strategic collaboration to develop and commercialize compounds in Takeda's early-to-mid-stage psychiatry pipeline. Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.